MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides
It is well-known that heparin and other glycosaminoglycans (GAGs) inhibit complement activation. It is however not known whether fractionation and/or modification of GAGs might deliver pathway-specific inhibition of the complement system. Therefore, we evaluated a library of GAGs and their derivativ...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00732/full |
id |
doaj-ab413b7510b74aa8a261d57227ebb687 |
---|---|
record_format |
Article |
spelling |
doaj-ab413b7510b74aa8a261d57227ebb6872020-11-25T03:20:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-04-011110.3389/fimmu.2020.00732503733MASP-2 Is a Heparin-Binding Protease; Identification of Blocking OligosaccharidesDitmer T. Talsma0Felix Poppelaars1Wendy Dam2Anita H. Meter-Arkema3Romain R. Vivès4Peter Gál5Geert-Jan Boons6Geert-Jan Boons7Pradeep Chopra8Annamaria Naggi9Marc A. Seelen10Stephan P. Berger11Mohamed R. Daha12Coen A. Stegeman13Jacob van den Born14the COMBAT ConsortiumDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsUniv. Grenoble Alpes, CNRS, CEA, IBS, Grenoble, FranceInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, HungaryDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, NetherlandsComplex Carbohydrate Research Center, University of Georgia, Athens, GA, United StatesComplex Carbohydrate Research Center, University of Georgia, Athens, GA, United StatesRonzoni Institute, Milan, ItalyDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, NetherlandsIt is well-known that heparin and other glycosaminoglycans (GAGs) inhibit complement activation. It is however not known whether fractionation and/or modification of GAGs might deliver pathway-specific inhibition of the complement system. Therefore, we evaluated a library of GAGs and their derivatives for their functional pathway specific complement inhibition, including the MASP-specific C4 deposition assay. Interaction of human MASP-2 with heparan sulfate/heparin was evaluated by surface plasmon resonance, ELISA and in renal tissue. In vitro pathway-specific complement assays showed that highly sulfated GAGs inhibited all three pathways of complement. Small heparin- and heparan sulfate-derived oligosaccharides were selective inhibitors of the lectin pathway (LP). These small oligosaccharides showed identical inhibition of the ficolin-3 mediated LP activation, failed to inhibit the binding of MBL to mannan, but inhibited C4 cleavage by MASPs. Hexa- and pentasulfated tetrasaccharides represent the smallest MASP inhibitors both in the functional LP assay as well in the MASP-mediated C4 assay. Surface plasmon resonance showed MASP-2 binding with heparin and heparan sulfate, revealing high Kon and Koff rates resulted in a Kd of ~2 μM and confirmed inhibition by heparin-derived tetrasaccharide. In renal tissue, MASP-2 partially colocalized with agrin and heparan sulfate, but not with activated C3, suggesting docking, storage, and potential inactivation of MASP-2 by heparan sulfate in basement membranes. Our data show that highly sulfated GAGs mediated inhibition of all three complement pathways, whereas short heparin- and heparan sulfate-derived oligosaccharides selectively blocked the lectin pathway via MASP-2 inhibition. Binding of MASP-2 to immobilized heparan sulfate/heparin and partial co-localization of agrin/heparan sulfate with MASP, but not C3b, might suggest that in vivo heparan sulfate proteoglycans act as a docking platform for MASP-2 and possibly prevent the lectin pathway from activation.https://www.frontiersin.org/article/10.3389/fimmu.2020.00732/fulllectin pathwayMASP-2tetrasaccharideheparincomplementglycosaminoglycans |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ditmer T. Talsma Felix Poppelaars Wendy Dam Anita H. Meter-Arkema Romain R. Vivès Peter Gál Geert-Jan Boons Geert-Jan Boons Pradeep Chopra Annamaria Naggi Marc A. Seelen Stephan P. Berger Mohamed R. Daha Coen A. Stegeman Jacob van den Born the COMBAT Consortium |
spellingShingle |
Ditmer T. Talsma Felix Poppelaars Wendy Dam Anita H. Meter-Arkema Romain R. Vivès Peter Gál Geert-Jan Boons Geert-Jan Boons Pradeep Chopra Annamaria Naggi Marc A. Seelen Stephan P. Berger Mohamed R. Daha Coen A. Stegeman Jacob van den Born the COMBAT Consortium MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides Frontiers in Immunology lectin pathway MASP-2 tetrasaccharide heparin complement glycosaminoglycans |
author_facet |
Ditmer T. Talsma Felix Poppelaars Wendy Dam Anita H. Meter-Arkema Romain R. Vivès Peter Gál Geert-Jan Boons Geert-Jan Boons Pradeep Chopra Annamaria Naggi Marc A. Seelen Stephan P. Berger Mohamed R. Daha Coen A. Stegeman Jacob van den Born the COMBAT Consortium |
author_sort |
Ditmer T. Talsma |
title |
MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides |
title_short |
MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides |
title_full |
MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides |
title_fullStr |
MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides |
title_full_unstemmed |
MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides |
title_sort |
masp-2 is a heparin-binding protease; identification of blocking oligosaccharides |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2020-04-01 |
description |
It is well-known that heparin and other glycosaminoglycans (GAGs) inhibit complement activation. It is however not known whether fractionation and/or modification of GAGs might deliver pathway-specific inhibition of the complement system. Therefore, we evaluated a library of GAGs and their derivatives for their functional pathway specific complement inhibition, including the MASP-specific C4 deposition assay. Interaction of human MASP-2 with heparan sulfate/heparin was evaluated by surface plasmon resonance, ELISA and in renal tissue. In vitro pathway-specific complement assays showed that highly sulfated GAGs inhibited all three pathways of complement. Small heparin- and heparan sulfate-derived oligosaccharides were selective inhibitors of the lectin pathway (LP). These small oligosaccharides showed identical inhibition of the ficolin-3 mediated LP activation, failed to inhibit the binding of MBL to mannan, but inhibited C4 cleavage by MASPs. Hexa- and pentasulfated tetrasaccharides represent the smallest MASP inhibitors both in the functional LP assay as well in the MASP-mediated C4 assay. Surface plasmon resonance showed MASP-2 binding with heparin and heparan sulfate, revealing high Kon and Koff rates resulted in a Kd of ~2 μM and confirmed inhibition by heparin-derived tetrasaccharide. In renal tissue, MASP-2 partially colocalized with agrin and heparan sulfate, but not with activated C3, suggesting docking, storage, and potential inactivation of MASP-2 by heparan sulfate in basement membranes. Our data show that highly sulfated GAGs mediated inhibition of all three complement pathways, whereas short heparin- and heparan sulfate-derived oligosaccharides selectively blocked the lectin pathway via MASP-2 inhibition. Binding of MASP-2 to immobilized heparan sulfate/heparin and partial co-localization of agrin/heparan sulfate with MASP, but not C3b, might suggest that in vivo heparan sulfate proteoglycans act as a docking platform for MASP-2 and possibly prevent the lectin pathway from activation. |
topic |
lectin pathway MASP-2 tetrasaccharide heparin complement glycosaminoglycans |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2020.00732/full |
work_keys_str_mv |
AT ditmerttalsma masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT felixpoppelaars masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT wendydam masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT anitahmeterarkema masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT romainrvives masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT petergal masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT geertjanboons masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT geertjanboons masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT pradeepchopra masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT annamarianaggi masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT marcaseelen masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT stephanpberger masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT mohamedrdaha masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT coenastegeman masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT jacobvandenborn masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides AT thecombatconsortium masp2isaheparinbindingproteaseidentificationofblockingoligosaccharides |
_version_ |
1724617391803990016 |